Fair point on the P comparison. That said, I like people to understand that the human body is exquisitely complicated and the data from an n of 10 rarely holds when the n increases significantly.
I think we have the potential of strong results in both P and B-OM, I'm just not banking on either being out of the park home-runs. The company is too young to know exactly how and what conditions are best addresses and via what delivery means. Give the company five to ten more years of experience and I think IPIX is running dozens of trials to nail down those issues. That's when we might see B achieving Humira type results, across multiple conditions (if B really is as good as it appears to be).
As for P, I'd be okay with 20% PASI 75 on P and over the moon with anything north of 30% PASI 75. I even think a 15% PASI 75 could be of real value. This is an oral product with a proven, safe track record.
If B-OM is half as effective as what it showed earlier, it's a huge drug. I just don't want to have unrealistic expectations because in the end, if it works to any degree, the stock price will be significantly higher than it is now and my incredibly over-sized position will be back to green!
News 
Market Data 
Discover 
